Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT04891068Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Jan 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in breast cancer, sponsored by University of Illinois Chicago. Started Jan 2022; status: recruiting.
02
Drugs
azacitidine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04891068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891068.